About Clopidogrel Bisulfate (Form 2) API
Therapeutic CategoryCardiovascular-pt
CAS Number
120202-66-6
API Technology
Synthetic
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, CEP Submitted, Brazil DMF, EUDMF, Russia DMF, China DMF
Mechanism of Action
Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.
Indication
Plavix is a P2Y12 platelet inhibitor indicated for:
- Acute coronary syndrome
– For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), Plavix has been shown to reduce the rate of myocardial infarction (MI) and stroke.
– For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of MI and stroke. - Recent MI, recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the rate of MI and stroke.
Related APIs
Mavacamten -Portugese
Cardiovascular-pt
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!